Novo Nordisk

Novo Nordisk is a Danish company headquartered in Bagsvaerd, focused on diabetes, obesity, endocrinology and rare diseases, and a cornerstone of the Danish economy. Its GLP-1 medicines Ozempic and Wegovy reshaped the treatment of diabetes and obesity.

Facing intense competition from Eli Lilly, Novo Nordisk announced around 9,000 job cuts in 2025 under a new chief executive as part of a major restructuring.

Featured on:

Did you know that some of the world’s most important medicines come from Europe?

From Aspirin to mRNA vaccines: the European pharma companies still leading medical science.

Visit website

Featured on Euronomy?

Promote, advertise or partner with us

Leave your details and we will get back to you.

Add the Featured on Euronomy badge

Paste this snippet where you want the badge to appear. It links back to Euronomy.

Embed code

<a class="euronomy-featured" data-href="https://euronomy.eu/e/resilience/european-medicine/novo-nordisk/"></a>
<script src="https://euronomy.eu/scripts/badge.js" defer></script>

Or just link the image

<a href="https://euronomy.eu/e/resilience/european-medicine/novo-nordisk/" target="_blank" rel="noopener">
  <img src="https://euronomy.eu/assets/img/EuronomyFeatured.png" alt="Featured on Euronomy" width="200">
</a>